Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 8103327

Effects of ritanserin on the 3,4-methylenedioxymethamphetamine-induced decrease in striatal serotonin concentration and on the increase in striatal neurotensin and dynorphin A concentrations.

M Johnson·L G Bush·G R Hanson·J W Gibb
View original source ↗Export metadata ↓

Abstract

The concentration of serotonin (5-HT) measured in rat striatum was reduced to 75% of control 1 week after a single subcutaneous administration of dl-3,4-methylenedioxymethamphetamine (MDMA, 20 mg/kg). This decrease was prevented by pretreating the animals with ritanserin. Eighteen hours after MDMA (20 mg/kg), striatal concentrations of neurotensin-like immunoreactivity (NTLI) and of dynorphin A-like immunoreactivity (DLI) were increased to 250 and 487% of control, respectively, but ritanserin failed to prevent these changes. This study supports a role for 5-HT2 receptors in the mechanism by which a single high dose of MDMA induces neuronal damage to the serotonergic system, but not the MDMA-induced increase in central NTLI and DLI concentrations.

Explore related subjects

3,4-MethylenedioxyamphetamineAnimalsCorpus StriatumDesigner DrugsDynorphinsMaleN-Methyl-3,4-methylenedioxyamphetamineNeurotensinRatsRats, Sprague-DawleyRitanserinSerotoninJournal ArticleResearch Support, U.S. Gov't, P.H.S.

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Johnson, L G Bush, G R Hanson, J W Gibb. 1993-08-17. Effects of ritanserin on the 3,4-methylenedioxymethamphetamine-induced decrease in striatal serotonin concentration and on the increase in striatal neurotensin and dynorphin A concentrations.. https://doi.org/10.1016/0006-2952(93)90568-h

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1998

[Neurotoxicity of the drug Ecstasy. Functional consequences of serotonergic hypoactivity].

Ingestion of the increasingly popular designer drug, ecstasy, results in an acute increase in the brain's monoamines: serotonin, dopamine, and noradrenaline. Animal research involving ecstasy has shown lasting damage to serotonergic axons and terminals, leading to reduced serotonin transmission in the CNS. Moreover, several studies suggest that the ingestion of ecstasy may be toxic to the human serotonin system. In animals repeated ecstasy administration has not shown persistent behavioural changes. In humans long lasting alterations in sleep pattern, mental state, personality, and cognition have been reported after repeated ecstasy use. However, these results have not been replicated, and most of them originate from uncontrolled studies of rather small populations.

3,4-Methylenedioxyamphetamine↗
PubMed1998

Detection of designer drugs in human hair by ion mobility spectrometry (IMS).

Since its inception in the early 1970s under the name plasma chromatography, ion mobility spectrometry (IMS) has undergone great changes. It is now utilized more and more in forensic science laboratories where it is used to detect explosives and environmental pollutants [1-4] as well as its use in detecting drugs of abuse [5-8]. Although IMS is known for nearly 30 years now [9], relatively few cases of the application of ion mobility spectrometry to the analysis of human hair have been reported [10-12]. The authors report a new and quick method to rapidly screen and determine MDMA ('ecstasy', 'Adam') and MDEA ('Eve') in human hair. The proposed method using trihexylamine as internal standard resulted in a rapid procedure useful in screening human hair specimens for designer drugs.

3,4-Methylenedioxyamphetamine↗
PubMed1998

Synthesis and pharmacological evaluation of ring-methylated derivatives of 3,4-(methylenedioxy)amphetamine (MDA).

The three isomeric ring-methylated derivatives of the well-known hallucinogen and entactogen MDA (1a) were synthesized and evaluated for pharmacological activity as monoamine-releasing agents and as serotonin agonists. The 2-methyl derivative 2a and the 5-methyl derivative 2b were found to be more potent and more selective than the parent compound in inhibiting [3H]-serotonin accumulation in rat brain synaptosomal preparations. Their activity in vivo was confirmed in rats trained to discriminate serotonin-releasing agents and hallucinogens from saline. The results indicate that compounds 2a,b are among the most potent 5-HT-releasing compounds known and show promise as lead compounds in the search for antidepressant drugs that release serotonin rather than inhibit its uptake.

3,4-Methylenedioxyamphetamine↗